Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of “Buy” from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $30.83.

TYRA has been the topic of a number of recent research reports. UBS Group began coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Tuesday, February 18th.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the sale, the director now directly owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 21,998 shares of company stock valued at $344,818 in the last 90 days. 15.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. RA Capital Management L.P. grew its position in shares of Tyra Biosciences by 2.1% during the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after acquiring an additional 220,681 shares during the period. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences during the fourth quarter worth approximately $56,716,000. FMR LLC grew its holdings in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after purchasing an additional 26,187 shares during the period. Boxer Capital Management LLC purchased a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $28,185,000. Finally, Janus Henderson Group PLC raised its stake in shares of Tyra Biosciences by 63.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock worth $24,291,000 after buying an additional 679,124 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 1.1 %

NASDAQ:TYRA opened at $9.77 on Friday. The firm has a fifty day simple moving average of $12.46 and a 200-day simple moving average of $16.33. Tyra Biosciences has a 12 month low of $9.49 and a 12 month high of $29.60. The company has a market capitalization of $494.39 million, a P/E ratio of -6.07 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. Equities analysts forecast that Tyra Biosciences will post -1.57 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.